STAT3 and Alzheimer disease: The observation that desrhamnosyl acteoside inhibited the phosphorylation of JAK2, STAT1, and STAT3 indicates its potential anti-inflammatory effect mediated by regulating the JAK2/STAT1 signaling pathway, which is consistent with the known role of JAK inhibitors in AD treatment.